Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US

Medicine & Life Sciences

• niraparib 100%
• olaparib 83%
• Budgets 61%
• Platinum 56%
• Ovarian Neoplasms 49%
• Costs and Cost Analysis 33%
• Pharmacy 20%
• Prescription Fees 12%
• Deductibles and Coinsurance 10%
• Health Insurance Reimbursement 9%
• Ribose 9%
• Therapeutics 8%
• Drug Costs 8%
• Poly(ADP-ribose) Polymerases 8%
• Population Density 7%
• Health Services Needs and Demand 7%
• Disease Management 6%
• Disease Progression 5%
• Clinical Trials 4%
• Mutation 3%
• Pharmaceutical Preparations 2%

Social Sciences

• impact analysis 74%
• cancer 49%
• budget 43%
• costs 30%
• drug 8%
• adverse events 8%
• epidemiological data 8%
• market share 7%
• Clinical Trials 6%
• fee 5%
• medication 5%
• utilization 4%
• candidacy 4%
• monitoring 4%
• death 4%
• management 2%
• literature 2%
• time 2%